Decreased deiodinase activity after glucose load could lead to atherosclerosis in euthyroid women with polycystic ovary syndrome
Tóm tắt
Glucose and lipid disturbances, as well as higher tendency to atherosclerosis, are observed in women with polycystic ovary syndrome (PCOS). Thyroid hormones action has long been recognized as an important determinant of glucose and lipid homeostasis. Some studies suggest that even in euthyroid subjects, thyroid function may affect atherosclerosis risk factors. The aim of this study was to evaluate the relationships between thyroid hormonal status and glucose and lipid profile before and after oral glucose tolerance test (OGTT) in PCOS women in comparison to the control group. The study group included 98 women—60 women with PCOS and 38 women matched for age and BMI as a control group. OGTT with estimation of plasma glucose and lipids, as well as serum insulin and thyroid hormones (TH) concentrations was performed. Activity of peripheral deiodinases at baseline (SPINA-GD1) and at the 120 min of OGTT (SPINA-GD2) was calculated according to the formula by Dietrich et al. as a measure of T4–T3 conversion efficiency. Delta GD was estimated as SPINA-GD1–SPINA-GD2, and delta fT3 was calculated as a difference between fT3 before and after OGTT. We did not find differences in TH, SPINA-GDs, and plasma lipid concentrations between PCOS and control group before and after OGTT. Glucose load resulted in a decrease of level TSH, TC, TG, HDL-C, and LDL-C concentrations in women with PCOS, as well as in the control group (all p < 0.05). We found that GD (p = 0.01) and serum fT3 concentration (p = 0.0008) decreased during glucose load only in the PCOS group. We observed a positive relationship between delta fT3 and plasma TG concentration (r = 0.36, p = 0.004), delta GD and plasma TG concentration after glucose load (r = 0.34, p = 0.007), only in the PCOS group. We also found negative relationship between SPINA-GD2 and plasma TC concentration (r = −0.29, p = 0.02) after glucose load and positive relationship between delta GD and insulin at the 60 min of OGTT (r = 0.29, p = 0.02), only in the PCOS women. These data showed insufficient conversion of fT4 to fT3, as well as a relationship of SPINA-GDs with insulin, TC and TG in PCOS women after glucose load. It may suggest that disturbances in deiodinase activity after glucose load might promote atherosclerosis in PCOS women.
Tài liệu tham khảo
H.F. Escobar-Morreale, Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 14, 270–284 (2018)
S. Livadas, E. Diamanti-Kandarakis, Polycystic ovary syndrome: definitions, phenotypes and diagnostic approach. Front. Horm. Res. 40, 1–21 (2013)
G. Papadakis, E. Kandaraki, O. Papalou, A. Vryonidou, E. Diamanti-Kandarakis, Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol. 42, 340–355 (2017)
R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038–2049 (2010)
M. Jacewicz-Święcka, I. Kowalska, Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies. Diabetes Metab. Res. Rev. 34, e3054 (2018)
L.H. Duntas, Thyroid disease and lipids. Thyroid 12, 287–293 (2002)
O. Bakker, F. Hudig, S. Meijssen, W.M. Wiersinga, Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem. Biophys. Res. Commun. 249, 517–521 (1998)
J.L. Leonard, S.A. Mellen, P.R. Larsen, Thyroxine 5′-deiodinase activity in brown adipose tissue. Endocrinology 112, 1153–1155 (1983)
J.M. Bates, D.L. St Germain, V.A. Galton, Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat. Endocrinology 140, 844–851 (1999)
D. Salvatore, S.C. Low, M. Berry, A.L. Maia, J.W. Harney, W. Croteau et al. Type 3 lodothyronine deiodinase: cloning, in vitro expression, and functional analysis of the placental selenoenzyme. J. Clin. Invest. 96, 2421–2430 (1995)
B. Gereben, A.M. Zavacki, S. Ribich, B.W. Kim, S.A. Huang, W.S. Simonides et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr. Rev. 29, 898–938 (2008)
E. Gałecka, A. Kumor-Kisielewska, A. Orzechowska, M. Maes, P. Górski, J. Szemraj, Assessment of type 1 and type 3 deiodinase expression levels in depressive disorders. Acta Neurobiol. Exp. 77, 225–235 (2017)
S.L. Goede, M.K. Leow, J.W. Smit, J.W. Dietrich, A novel minimal mathematical model of the hypothalamus-pituitary-thyroid axis validated for individualized clinical applications. Math. Biosci. 249, 1–7 (2014)
S.L. Goede, M.K. Leow, J.W. Smit, H.H. Klein, J.W. Dietrich, Hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull. Math. Biol. 76, 1270–1287 (2014)
J.W. Dietrich, G. Landgrafe-Mende, E. Wiora, A. Chatzitomaris, H.H. Klein, J.E. Midgley et al. Calculated parameters of thyroid homeostasis: emerging tools for differential diagnosis and clinical research. Front. Endocrinol. 7, 57 (2016)
I. Kowalska, M. Straczkowski, A. Nikolajuk, A. Adamska, M. Karczewska-Kupczewska, E. Otziomek et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum. Reprod. 22, 1824–1829 (2007)
A. Vermeulen, L. Verdonck, J.M. Kaufman, A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666–3672 (1999)
A. Adamska, A. Łebkowska, A. Krentowska, M. Jacewicz, M. Górska, I. Kowalska, Relationship between serum gonadotropin concentrations and thyroid volume in women with polycystic ovary syndrome. Pol. Arch. Med. Wewn. 126, 891–894 (2016)
D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)
J.W. Dietrich, A. Stachon, B. Antic, H.H. Klein, S. Hering, The AQUA-FONTIS study: protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome. BMC Endocr. Disord. 8, 13 (2008)
J. Brunn, U. Block, G. Ruf, I. Bos, W.P. Kunze, P.C. Scriba, Volumetric analysis of thyroid lobes by real-time ultrasound (author’s transl). Dtsch. Med. Wochenschr. 106, 1338–1340 (1981)
A.C. Bianco, G. Anderson, D. Forrest, V.A. Galton, B. Gereben, B.W. Kim et al. American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid 24, 88–168 (2014)
A. Jabbar, A. Pingitore, S.H. Pearce, A. Zaman, G. Iervasi, S. Razvi, Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol. 14, 39–55 (2017)
A. Marsili, C. Aguayo-Mazzucato, T. Chen, A. Kumar, M. Chung, E.P. Lunsford et al. Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity. PLoS One 6, e20832 (2011)
E. Akarsu, H. Korkmaz, S. Oguzkan Balci, E. Borazan, S. Korkmaz, M. Tarakcioglu, Subcutaneous adipose tissue type II deiodinase gene expression reduced in obese individuals with metabolic syndrome. Exp. Clin. Endocrinol. Diabetes 124, 11–15 (2016)
D. Mentuccia, M.J. Thomas, G. Coppotelli, L.J. Reinhart, B.D. Mitchell, A.R. Shuldiner et al. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid 15, 1223–1227 (2005)
L.H. Canani, C. Capp, J.M. Dora, E.L. Meyer, M.S. Wagner, J.W. Harney et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 90, 3472–3478 (2005)
J.M. Dora, W.E. Machado, J. Rheinheimer, D. Crispim, A.L. Maia, Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur. J. Endocrinol. 163, 427–434 (2010)
R.P. Peeters, A.W. van den Beld, H. van Toor, A.G. Uitterlinden, J.A. Janssen, S.W. Lamberts et al. A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans. J. Clin. Endocrinol. Metab. 90, 256–263 (2005)
F.J. de Jong, R.P. Peeters, T. den Heijer, W.M. van der Deure, A. Hofman, A.G. Uitterlinden et al. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J. Clin. Endocrinol. Metab. 92, 636–640 (2007)
A. Chatzitomaris, R. Hoermann, J.E. Midgley, S. Hering, A. Urban, B. Dietrich et al. Thyroid allostasis-adaptive responses of thyrotropic feedback control to conditions of strain, stress, and developmental programming. Front. Endocrinol. 8, 163 (2017)
J.W. Dietrich, G. Landgrafe, E.H. Fotiadou, TSH and thyrotropic agonists: key actors in thyroid homeostasis. J. Thyroid Res. 2012, 351864 (2012)
K. Ogita, M. Ai, A. Tanaka, Y. Ito, T. Hirano, G. Yoshino et al. Serum concentration of small dense low-density lipoprotein-cholesterol during oral glucose tolerance test and oral fat tolerance test. Clin. Chim. Acta 387, 36–41 (2008)
E. Ortega, J. Koska, N. Pannacciulli, J.C. Bunt, J. Krakoff, Free triiodothyronine plasma concentrations are positively associated with insulin secretion in euthyroid individuals. Eur. J. Endocrinol. 158, 217–221 (2008)
M. Moreno, E. Silvestri, R. De Matteis, P. de Lange, A. Lombardi, D. Glinni et al. 3,5-Diiodo-l-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. FASEB J. 25, 3312–3324 (2011)
Y. Lin, Z. Sun, Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes. Br. J. Pharmacol. 162, 597–610 (2011)
G. Dimitriadis, P. Mitrou, V. Lambadiari, E. Boutati, E. Maratou, D.B. Panagiotakos et al. Insulin action in adipose tissue and muscle in hypothyroidism. J. Clin. Endocrinol. Metab. 91, 4930–4937 (2006)
P. Langer, E. Martino, L. Ksinantova, L. Glasso, M. Vigas, Changes of serum TSH level during oral glucose tolerance test: comparison of morning and evening test with plain circadian TSH rhythm. Endocr. Regul. 34, 145–150 (2000)
G. De Pergola, A. Ciampolillo, S. Paolotti, P. Trerotoli, R. Giorgino, Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin. Endocrinol. 67, 265–269 (2007)
C.M. Kitahara, E.A. Platz, P.W. Ladenson, A.M. Mondul, A. Menke, A. Berrington de González, Body fatness and markers of thyroid function among U.S. men and women. PLoS One 7, e34979 (2012)
C. Dall’Asta, M. Paganelli, A. Morabito, P. Vedani, M. Barbieri, G. Paolisso et al. Weight loss through gastric banding: effects on TSH and thyroid hormones in obese subjects with normal thyroid function. Obesity 18,854–857 (2010)
T. Reinehr, Obesity and thyroid function. Mol. Cell. Endocrinol. 316, 165–171 (2010)